154 related articles for article (PubMed ID: 36268606)
1. Atopic dermatitis-like graft-versus-host disease treated with dupilumab.
Larijani M; Zarowin D; Wohlschlaeger A; Perman MJ; Treat JR
Pediatr Dermatol; 2023 Mar; 40(2):320-322. PubMed ID: 36268606
[TBL] [Abstract][Full Text] [Related]
2. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series.
Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304
[TBL] [Abstract][Full Text] [Related]
3. Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
Tierney E; Evans P; Broderick V; Wynn R; Irvine AD
Br J Dermatol; 2024 Mar; 190(4):581-583. PubMed ID: 38123149
[No Abstract] [Full Text] [Related]
4. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.
Strober B; Mallya UG; Yang M; Ganguli S; Gadkari A; Wang J; Sierka D; Delevry D; Kimball AB
JAMA Dermatol; 2022 Feb; 158(2):142-150. PubMed ID: 34910086
[TBL] [Abstract][Full Text] [Related]
5. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
7. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
8. An updated reappraisal of dupilumab in children and adolescents with moderate-severe atopic dermatitis.
Ciprandi G; Licari A; Tosca MA; Miraglia Del Giudice M; Belloni Fortina A; Marseglia GL
Pediatr Allergy Immunol; 2024 Jun; 35(6):e14181. PubMed ID: 38934228
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Silverberg JI; Simpson EL; Boguniewicz M; De Bruin-Weller MS; Foley P; Kataoka Y; Bégo-Le-Bagousse G; Chen Z; Shumel B; Chao J; Rossi AB
Acta Derm Venereol; 2021 Nov; 101(11):adv00585. PubMed ID: 34618162
[TBL] [Abstract][Full Text] [Related]
10. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
11. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
Paller AS; Siegfried EC; Thaçi D; Wollenberg A; Cork MJ; Arkwright PD; Gooderham M; Beck LA; Boguniewicz M; Sher L; Weisman J; O'Malley JT; Patel N; Hardin M; Graham NMH; Ruddy M; Sun X; Davis JD; Kamal MA; Khokhar FA; Weinreich DM; Yancopoulos GD; Beazley B; Bansal A; Shumel B
J Am Acad Dermatol; 2020 Nov; 83(5):1282-1293. PubMed ID: 32574587
[TBL] [Abstract][Full Text] [Related]
13. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
15. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective.
Chia SY; Wee LWY; Koh MJA
Dermatol Ther; 2021 May; 34(3):e14933. PubMed ID: 33751751
[TBL] [Abstract][Full Text] [Related]
17. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
20. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Paller AS; Beck LA; Blauvelt A; Siegfried EC; Cork MJ; Wollenberg A; Chen Z; Khokhar FA; Vakil J; Zhang A; Bansal A; Cyr SL
Pediatr Dermatol; 2022 Mar; 39(2):187-196. PubMed ID: 35083774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
